Prognostic biomarkers for patients with advanced renal cell carcinoma treated with VEGF-targeted tyrosine kinase inhibitors

References

• ZismanAPantuckAJDorseyFImproved prognostication of renal cell carcinoma using an integrated staging systemJ Clin Oncol2001191649165711250993
   PubMed Web of Science ®Google Scholar
• FrankIBluteMLChevilleJCLohseCMWeaverALZinckeHAn outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN scoreJ Urol20021682395240012441925
   PubMed Web of Science ®Google Scholar
• MotzerRJMazumdarMBacikJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol1999172530254010561319
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBARussoPMazumdarMInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol20022028929611773181
   PubMed Web of Science ®Google Scholar
• HoffmeisterIRiesenbackLBjererSValidation of MSKCC-criteria in metastatic renal cancer patients treated with sorafenib or sunitinibJ Clin Oncol201129Suppl 7Abstr 401
   Web of Science ®Google Scholar
• HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multi-center studyJ Clin Oncol2009275794579919826129
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMExternal validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based studyLancet Oncol20131414114823312463
   PubMed Web of Science ®Google Scholar
• VickersMMChoueiriTKRogersMClinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapyUrology20107643043420223508
   PubMed Web of Science ®Google Scholar
• ChoueiriTKGarciaJAElsonPClinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapyCancer200711054355017577222
   PubMed Web of Science ®Google Scholar
• ManolaJRoystonPElsonPPrognostic model for survival in patients with metastatic renal cell carcinoma: results from the International Kidney Cancer Working GroupClin Cancer Res2011175443545021828239
   PubMed Web of Science ®Google Scholar
• Al-MarrawiMYRiniBIHarshmanLCThe association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patientsTarget Oncol192013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• SeidelCBuschJWeikertSProgression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinomaEur J Cancer2012481023103022436979
   PubMed Web of Science ®Google Scholar
• RixeOBillemontBIzzedineHHypertension as a predictive factor of sunitinib activityAnn Oncol200718111717586751
   PubMed Web of Science ®Google Scholar
• RiniBICohenDPLuDRHypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinibJ Natl Cancer Inst201110376377321527770
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialLancet20113781931193922056247
   PubMed Web of Science ®Google Scholar
• RiniBIMichaelsonMDRosenbergJEAntitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory advanced renal cell carcinomaJ Clin Oncol2008263743374818669461
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib for treatment for renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialJ Clin Oncol2009273312331819451442
   PubMed Web of Science ®Google Scholar
• EscudierBRavaudANegrierSUpdate on the AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysisJ Clin Oncol200826SupplAbstr 5025
   Web of Science ®Google Scholar
• HegdePSJubbAMChenDPredictive impact of circulating vascular endothelial growth factor in four Phase III trials evaluating bevacizumabClin Cancer Res20131992993723169435
   PubMed Web of Science ®Google Scholar
• PenaCLathiaLShanMEscudierBBukowskiRMBiomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trialClin Cancer Res2010164853486320651059
   PubMed Web of Science ®Google Scholar
• Yann-AlexandreVBeuselinckBWolterPPrognostic impact of baseline serum C-reactive protein in metastatic renal cell carcinoma treated with sunitinibJ Clin Oncol201331SupplAbstr 425
   Web of Science ®Google Scholar
• NegrierSPerolDMenetrier-CauxCInterleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6- from the Groupe Francais d’ImmunotherapieJ Clin Oncol2004222371237815197198
   PubMed Web of Science ®Google Scholar
• MonteroAJDiaz-MonteroCMMillikanRECytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survivalAnn Oncol2009201682168719541791
   PubMed Web of Science ®Google Scholar
• TranHTLiuYZuritaAJPrognostic or predictive plasma cytokine and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trialsLancet Oncol20121382783722759480
   PubMed Web of Science ®Google Scholar
• ChoueiriTKVaziriSAJaegerEvon Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinomaJ Urol200818086086518635227
   PubMed Web of Science ®Google Scholar
• BianconiMScartozziMFaloppiLEffect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatmentJ Clin Oncol201331SupplAbstr 388
   Web of Science ®Google Scholar
• JonaschEThakurSSircarKImpact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agentsJ Clin Oncol201331SupplAbstr 393
   Web of Science ®Google Scholar
• PatelPChadalavadaRIshillNHypoxia-inducible factor (HIF) 1α and 2α levels in cell lines and human tumor predicts response to sunitinib in renal cell carcinoma (RCC)J Clin Oncol200826SupplAbstr 5008
   Web of Science ®Google Scholar
• BuiMHSeligsonDHanKRCarbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapyClin Cancer Res2003980281112576453
   PubMed Web of Science ®Google Scholar
• ChoueiriTKReganMMRosenbergJECarbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapyBJU Int201010677277820230385
   PubMed Web of Science ®Google Scholar
• ChoueiriTKChengSQuAQPastorekJAtkinsMBSignorettiSCarbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET)Urol Oncol2012 doi:pii: S1078-1439(12)00246–3
   Web of Science ®Google Scholar
• VarelaITarpeyPRaineKExome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinomaNature201146953954221248752
   PubMed Web of Science ®Google Scholar
• Peña-LlopisSVega-Rubín-de-CelisSLiaoABAP1 loss defines a new class of renal cell carcinomaNat Genet20124475175922683710
   PubMed Web of Science ®Google Scholar
• DalglieshGLFurgeKGreenmanCSystematic sequencing of renal carcinoma reveals inactivation of histone modifying genesNature201046336036320054297
   PubMed Web of Science ®Google Scholar
• LichnerZScorilasAWhiteNMThe chromatin remodeling gene ARID1A is a new prognostic marker in clear cell renal cell carcinomaAm J Pathol20131821163117023416164
   PubMed Web of Science ®Google Scholar
• HakimiAAChenYBWrenJClinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinomaEur Urol20136384885423036577
   PubMed Web of Science ®Google Scholar
• KapurPPeña-LlopisSChristieAEffects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validationLancet Oncol20131415916723333114
   PubMed Web of Science ®Google Scholar